Enliven Therapeutics (ELVN) EBIT (2019 - 2026)
Enliven Therapeutics (ELVN) reported EBIT of -$27.8 million for Q1 2026, up 12.21% on a YoY basis from -$24.8 million in Q1 2025, and up 18.85% sequentially from -$34.3 million in Q4 2025.
Enliven Therapeutics (ELVN) EBIT (2019 - 2026) Analysis & Trends
Enliven Therapeutics (ELVN) has 8 years of EBIT data on file, last reported at -$27.8 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT rose 12.21% year-over-year to -$27.8 million; the trailing twelve-month figure through Mar 2026 stood at -$115.8 million (down 5.01% YoY), and the FY2025 full-year result was -$119.7 million, down 14.45% from the prior year.
- EBIT climbed to -$27.8 million in Q1 2026, from -$34.3 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$8.7 million in Q1 2022 to a low of -$34.3 million in Q4 2025.
- A 5-year average of -$22.0 million and a median of -$24.6 million in 2024 frame the typical range for EBIT.
- Across the five-year window, EBIT surged 31.54% in 2022 and sank 123.64% in 2023, its largest moves.
- Tracing ELVN's EBIT over 5 years: stood at -$10.2 million in 2022, then plunged by 123.64% to -$22.7 million in 2023, then slipped by 18.33% to -$26.9 million in 2024, then slipped by 27.47% to -$34.3 million in 2025, then increased by 18.85% to -$27.8 million in 2026.
- Business Quant data shows ELVN's EBIT at -$27.8 million in Q1 2026, -$34.3 million in Q4 2025, and -$25.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Enliven Therapeutics | 3.22 Bn | 3.22 Bn | - | -27.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.82 Mn |
| Dec 31, 2025 | -34.29 Mn |
| Sep 30, 2025 | -25.10 Mn |
| Jun 30, 2025 | -28.58 Mn |
| Mar 31, 2025 | -31.69 Mn |
| Dec 31, 2024 | -26.90 Mn |
| Sep 30, 2024 | -27.07 Mn |
| Jun 30, 2024 | -24.60 Mn |
| Mar 31, 2024 | -25.99 Mn |
| Dec 31, 2023 | -22.73 Mn |
| Sep 30, 2023 | -24.25 Mn |
| Jun 30, 2023 | -20.13 Mn |
| Mar 31, 2023 | -16.42 Mn |
| Dec 31, 2022 | -10.16 Mn |
| Sep 30, 2022 | -10.93 Mn |
| Jun 30, 2022 | -9.02 Mn |
| Mar 31, 2022 | -8.68 Mn |
| Dec 31, 2021 | -14.33 Mn |
| Sep 30, 2021 | -13.66 Mn |
| Jun 30, 2021 | -13.17 Mn |